Summary & Overview
HCPCS Q9986: Hydroxyprogesterone Caproate (Makena) Injection, 10 mg
HCPCS Level II code Q9986 denotes injection of hydroxyprogesterone caproate (Makena), 10 mg, a progestin product used in obstetric care. Nationally, this drug-level HCPCS code matters for documenting clinic-administered medication, tracking utilization, and distinguishing payer coverage and billing pathways for specialty injectable therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how Q9986 is used clinically, common sites of service for administration, and the types of benchmarks and policy elements typically relevant for this code—coverage determinations, coding clarity for medication dose reporting, and implications for pharmacy versus clinic billing. The summary highlights where to expect variability across payers in prior authorization and reimbursement policies and outlines the kinds of data and policy updates that affect billing for injectable obstetric medications.
This piece provides clinicians, billing specialists, and policy analysts with the clinical context and billing focus needed to align documentation and claims with payer requirements and to anticipate areas where policy guidance or updates may influence claims processing.
Billing Code Overview
HCPCS Level II code Q9986 represents an injection of hydroxyprogesterone caproate (Makena), 10 mg. This code is used to report administration of the specific progestin formulation supplied in premeasured doses for obstetric use.
Service type: Medication injection / pharmacy-administered drug.
Typical site of service: Outpatient clinics, physician offices, and ambulatory infusion centers where intramuscular injections or clinic-administered medications are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a pregnant person with a history of spontaneous preterm birth at less than 37 weeks gestation in a prior pregnancy, presenting for preventive therapy during the current singleton pregnancy. After obstetric assessment confirms eligibility (singleton pregnancy, prior spontaneous preterm delivery, no contraindications such as current thromboembolic disease or progesterone-sensitive malignancy), the clinician prescribes intramuscular hydroxyprogesterone caproate, Q9986 (10 mg per unit). The clinical workflow includes: initial eligibility screening at a prenatal visit (medical history, review of prior delivery records), informed counseling about risks and benefits, ordering the medication through the outpatient pharmacy or infusion clinic, scheduling weekly intramuscular injections starting at 16–20 weeks gestation through 36 weeks or delivery, documenting each administration in the medical record, and monitoring for injection site reactions and adverse events at each visit. Nursing or clinic staff prepare and administer the Q9986 injection, verify patient identity and consent, apply appropriate billing with the Q9986 HCPCS Level II code, and record lot number and expiration for medication safety documentation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |